Navigation Links
New analysis provides clearer picture of cancer risks associated with Lynch syndrome
Date:2/14/2012

People with Lynch syndrome have a genetic mutation that gives them a high risk of several types of cancer including bowel cancer. The genes that are damaged can't repair any errors that occur in our DNA.

The study, which has been published in the Journal of Clinical Oncology, confirmed the increased risk of cancers already known to be associated with Lynch syndrome, including colon, uterus, ovary, kidney, stomach, and bladder cancers. They also found those with Lynch syndrome faced a moderately increased risk of developing breast and pancreatic cancer.

The researchers, led by Dr Aung Ko Win, and Associate Professor Mark Jenkins, at The University of Melbourne's School of Population Health, followed 450 people with a mutation in one of the four mismatch repair genes associated with Lynch syndrome, and more than 1000 of their relatives who were not carriers of these mutations. Study participants were evaluated every five years at recruitment centres affiliated with the Colon Cancer Family Registry in Australia, New Zealand, Canada and the US.

After five years, those with Lynch syndrome had a 20-fold greater risk of colorectal cancer; a 30-fold greater risk of endometrial (uterine) cancer; a 19-fold higher risk of ovarian cancer; an 11-fold greater risk of kidney cancer; a 10-fold greater risk of pancreatic, stomach, and bladder cancers; and a four-fold greater risk of breast cancer. People with Lynch syndrome also tended to be diagnosed with these cancers at an earlier age than people in the general population.

The researchers said their findings regarding breast cancer were unexpected. They said further studies were needed to determine if ages at mammographic screening or methods such as use of MRI should be recommended for people with Lynch syndrome. Currently, individuals with Lynch syndrome typically undergo colonoscopy at an earlier age than the general population, but no other special screening regimens have been agreed upon.

This is also the largest study to date of cancer risk for non-carriers of family specific mutations.

"Our study revealed that these people have an average risk of developing cancer as opposed to the high risk of their mutation-carrying close relatives and hence do not need to worry unnecessarily and over screen to detect cancer," said Associate Professor Jenkins.

"While not a common condition, approximately 20,000 Australians have Lynch syndrome and a very high risk of cancer. Over time, as improved screening methods become available, the findings may help doctors refine screening guidelines for breast, uterus, colon and other cancers among patients with Lynch syndrome. In the meantime, genetic testing will give people a clearer indication of their real risk level and clarify what they could or should not do to reduce their risks of cancer."

People who think they might be at increased risk for cancer due to family history should attend a Family Cancer Clinics for genetic testing and advice so cancers can be detected and treated as early as possible.


'/>"/>
Contact: Annie Rahilly
arahilly@unimelb.edu.au
61-390-355-380
University of Melbourne
Source:Eurekalert

Related medicine news :

1. Certain Cancer Drugs May Have Fatal Side Effects: Analysis
2. Louisiana Tech professor co-edits book on computational analysis of human eye
3. Analysis does not support genetic test before use of anti-clotting drug
4. ORNL image analysis prowess advances retina research
5. First analysis of tumor-suppressor interactions with whole genome in normal human cells
6. Results of the PARTNER Trial Cohort A cost effectiveness analysis reported
7. New analysis from the Nurses Health Study: Association of alcohol with risk of breast cancer
8. Analysis reveals malaria, other diseases as ancient, adaptive and persistent foes
9. Psychopathic killers: Computerized text analysis uncovers the word patterns of a predator
10. IU analysis changing diagnosis and management of initial UTIs in young children
11. UBC researchers create more powerful lab-on-a-chip for genetic analysis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... March 23, 2017 , ... Ogden Clinic, the largest ... centric payment system, to expand its focus on patient care by providing an ... , “At Ogden Clinic, we are working to become a different type ...
(Date:3/23/2017)... ... 23, 2017 , ... “The Trainer”: an electrifying and suspenseful gunslinger novel ... writer with an active imagination and an enthusiasm for action and adventure stories. ... Wild Bill Hart, who sat looking at the thirty-three notches that lined the edges ...
(Date:3/23/2017)... ... March 23, 2017 , ... Vortex Biosciences, provider of circulating ... in circulating tumor cells using microfluidic western blotting” in Nature Communications on March ... technology to capture CTCs and a microfluidic single-CTC resolution Western blot from ...
(Date:3/22/2017)... ... March 22, 2017 , ... ... publication of the first issue of its companion print magazine. The new magazine, ... cosmetic surgery thanks to information provided by board-certified doctors from across the country. ...
(Date:3/22/2017)... (PRWEB) , ... March 22, 2017 , ... ... California Bay Area providing insurance assistance, financial planning, and related services to residents ... Species International to promote awareness of threatened species and wild lands. , Endangered ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... March 23, 2017 On ... the trading session at 5,821.64, up 0.48%; the ... finish at 20,661.30; and the S&P 500 closed ... based as six out of nine sectors ended ... initiated reports coverage on the following Medical Instruments ...
(Date:3/23/2017)... , March 23, 2017 BioLineRx Ltd. ... immunology, announced today that it has acquired Agalimmune Ltd., a ... consideration consisted of a $6 million upfront payment, of which ... shares. Additional future payments may be made based on development ... ...
(Date:3/23/2017)... AVIV, Israel, March 23, 2017  Galmed Pharmaceuticals ... the "Company"), a clinical-stage biopharmaceutical company focused on ... the treatment of nonalcoholic steatohepatitis, or NASH, and ... the three and twelve months ended December 31, 2016, ... completed pre-clinical studies demonstrating Aramchol™,s potential direct effect ...
Breaking Medicine Technology: